Intended for healthcare professionals

Rapid response to:

Papers

Systematic review of lipid lowering for primary prevention of coronary heart disease in diabetes

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7388.528 (Published 08 March 2003) Cite this as: BMJ 2003;326:528

Rapid Response:

Correction to Table

Dear Editor and Readers,

We recently noticed an error in the Table of our systematic review of
lipid lowering for the primary prevention of coronary heart disease in
diabetes (1). The Table reads that 1,037 patients with diabetes were
randomized in the WOSCOPS trial, when in fact the correct number of
diabetic patients is 76 (2). The results and conclusions of our
systematic review were not affected by this error.

Sincerely,

Apoor S. Gami, MD

Victor Montori, MD, MSc

References:

(1) Gami AS, Montori VM, Erwin PJ, Khan MA, Smith SA; Evidence in
Diabetes Enquiry System (EVIDENS) Research Group. Systematic review of
lipid lowering for primary prevention of coronary heart disease in
diabetes. BMJ 2003;326:528-529.

(2) Shepherd J, Cobbe S, Ford I, Isles CG, Lorimer AR, MacFarlane PW,
et al. Prevention of coronary heart disease with pravastatin in men with
hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N
Engl J Med 1995;333:1301-7.

Competing interests:
None declared

Competing interests: No competing interests

21 December 2004
Apoor S Gami
Division of Cardiovascular Diseases
Victor M. Montori
Mayo Clinic College of Medicine